Unlike IDH1-wildtype gliomas, IDH1 (R132H) mutations suppress PD-L1 expression through DNA hypermethylation, leading to a less immunosuppressive microenvironment (Figure 12) [23]. This evidence concerns the gene IDH1 and central nervous system cancer.